Chemotherapy-rewiring of control and TP53-deficient lymphoma B-cells’ proteome. (A-D) shCTRL and shTP53 hMB cells were treated with 3 µM mafosfamide or vehicle (untreated) for 6 hours, and their proteomic profiles were analyzed by mass spectrometry label-free protein quantification (n = 3). (A) Workflow of the experiment (left panel). Bar plot of the number of up- and downregulated proteins that are differentially expressed in shTP53 hMB cells in comparison with shCTRL hMB cells, either in untreated or mafosfamide-treated condition (central panel). Venn diagram illustrating the total number of significant proteins specifically or commonly regulated by TP53 in either untreated or mafosfamide-treated condition. (B-D) Enriched cellular component GO terms identified in the analysis of significantly regulated proteins by TP53 expression in untreated (-) and mafosfamdie-treated (+) hMB cells. (B) Sphere sizes represent the number of proteins associated to every GO term, whereas the color indicates the adjusted P-value (lower panel). (C-D) Network interaction depicting the linkage of proteins and selected CC-GO terms identified in the comparison analysis between TP53-deficient and control hMB cells upon (C) vehicle (untreated) or (D) mafosfamide treatment. Sphere sizes represent the number of proteins associated to every GO term. Green and red nodes highlight down- and upregulated proteins, respectively. Proteins involved in EV biogenesis or release have been highlighted.